CEL-SCI Corp CVM:NYSE American

Earnings Announcement Next Earnings date is expected on 02/13/2023
Last Price$2.77AMEX Previous Close - Last Trade as of 6:30PM ET 2/08/23

Today's Change-0.01(0.36%)
Bid (Size)$2.67 (1)
Ask (Size)$3.12 (1)
Day Low / High$2.72 - 2.81
Volume30.4 K
 

View Biotechnology IndustryPeer Comparison as of 02/08/2023

 

CEL-SCI Corp ( NYSE MKT LLC )

Price: $2.77
Change: -0.01 (0.36%)
Volume: 30.4 K
6:30PM ET 2/08/2023
 
 

X4 Pharmaceuticals Inc ( NASDAQ )

Price: $0.96
Change: -0.04 (3.76%)
Volume: 551.7 K
4:00PM ET 2/08/2023
 
 

Aravive Inc ( NASDAQ )

Price: $1.93
Change: -0.16 (7.66%)
Volume: 130.5 K
4:00PM ET 2/08/2023
 
 

Precision BioSciences Inc ( NASDAQ )

Price: $1.13
Change: -0.05 (4.24%)
Volume: 293.7 K
4:00PM ET 2/08/2023
 
 

Galectin Therapeutics Inc ( NASDAQ )

Price: $1.74
Change: -0.14 (7.45%)
Volume: 240.6 K
4:00PM ET 2/08/2023
 

Read more news Recent News

--EF Hutton Cuts Price Target on Cel-Sci to $16 From $17, Maintains Buy Rating
8:06AM ET 12/29/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Premarket Gainers
8:06AM ET 10/12/2022 MT Newswires

Hempacco (HPCO) shares surged 63% premarket Wednesday after the company reported revenue of about $2.8 million for the six months ended June 30, a 486%...

Cel-Sci Reports Positive Data From Phase 3 Study Of Neoadjuvant Multikine In Locally Advanced Head, Neck Cancer
1:12PM ET 9/12/2022 MT Newswires

Cel-Sci (CVM) reported Monday positive data from a phase 3 study of its Neoadjuvant Multikine injection in terms of tumor response and overall survival in...

Cel-Sci Says Positive Findings From Phase 3 Trial of Head, Neck Cancer Drug Now Published
10:54AM ET 8/19/2022 MT Newswires

Cel-Sci (CVM) said Friday that positive findings from its phase 3 trial of Multikine in head and neck cancer have been published on clinicaltrials.gov per...

View all Commentary and Analysis

CEL-SCI: More Shareholder Pain Likely Ahead
10:09AM ET 12/13/2022 Seeking Alpha

CEL-SCI's Multikine - Potential 21st Century Game-Changing Cancer Drug On The Horizon
11:41AM ET 9/30/2022 Seeking Alpha

CEL-SCI: Enduring Challenges
8:00AM ET 8/03/2022 Seeking Alpha

CEL-SCI: No Rush Here
12:22PM ET 2/24/2022 Seeking Alpha

Company Profile

Business DescriptionCEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA. View company web site for more details
Address8229 Boone Boulevard
Vienna, Virginia 22182
Phone+1.703.506.9460
Number of EmployeesN/A
Recent SEC Filing02/08/2023SC 13G/A
CEO, Chief Financial Officer, Treasurer & DirectorGeert R. Kersten
Secretary & Senior Vice President-OperationsPatricia B. Prichep
Chief Scientific OfficerEyal Talor
Vice President-Quality AssuranceWilliam Jones

Company Highlights

Price Open$2.76
Previous Close$2.78
52 Week Range$1.88 - 6.51
Market Capitalization$121.0 M
Shares Outstanding43.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/13/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.88
Beta vs. S&P 500N/A
Revenue$476.6 K
Net Profit MarginN/A
Return on Equity-87.71%

Analyst Ratings as of 04/06/2022

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset